ALMR Overview

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.

Wall Street analysts forecast ALMR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alamar Biosciences Inc revenue for the last quarter amounts to 26.04M USD, increased 98.88

Alamar Biosciences Inc. EPS for the last quarter amounts to -0.32 USD, increased 166.67

Alamar Biosciences Inc (ALMR) has 222 emplpoyees as of May 30 2026.

Today ALMR has the market capitalization of 1.42B USD.